Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2004; 91(05): 1050
DOI: 10.1055/s-0037-1614203
DOI: 10.1055/s-0037-1614203
Letters to the Editor
Mechanism of action of drotrecogin alfa activated (rhAPC)
Further Information
Publication History
Received
17 December 2003
Accepted
09 February 2004
Publication Date:
15 December 2017 (online)
-
References
- 1 Dhainaut JF, Yan SB, Margolis BD. et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90 (04) 642-53.
- 2 Bernard GR, Vincent JL, Laterre PF. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344 (10) 699-709.
- 3 Crowther MA, Marshall JC. Continuing challenges of sepsis research. JAMA 2001; 286 (15) 1894-6.
- 4 Angus DC, Crowther MA. Unraveling severe sepsis: why did OPTIMIST fail and what’s next?. JAMA 2003; 290 (02) 256-8.
- 5 Derhaschnig U, Reiter R, Knobl P. et al. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxe-mia. Blood 2003; 102 (06) 2093-8.
- 6 Taylor Jr F. Comment on “Drotrecogin Alfa (activated) (recombinant human protein C, rhAPC) reduces host coagulopathy response in patients with severe sepsis”. Thromb Haemost 2003; 90 (04) 560-1.